PL EN


Preferences help
enabled [disable] Abstract
Number of results
2015 | 13 | 1 | 5-10
Article title

Rak endometrium typu I i II – nowe spojrzenie na etiologię i przebieg kliniczny

Content
Title variants
EN
Type I and II endometrial cancer – a new look at the etiology and clinical course
Languages of publication
EN PL
Abstracts
EN
Endometrial cancer is the most frequent malignancy of female genital organs in more developed countries. It is a heterogeneous tumor with variable risk factors, precancerous conditions, clinical course and prognosis. The majority of cases are sporadic, however endometrial cancer develops in around 8–12% of women with Lynch syndrome, who are at increased risk of this disease. MLH1, MSH2 and MSH6 mutations are observed with equal frequency. Recent molecular studies on endometrial cancer indicate that the classic division into two types according to Bokhman is insufficient, particularly with respect to type II which is less common, and which includes both serous carcinomas and clear-cell carcinomas. Endometrial intraepithelial carcinoma is considered a precursor lesion for uterine serous carcinoma. In immunohistochemical tests (p53, Ki67, ER and PR) it resembles a precursor lesion for ovarian serous carcinoma, possibly indicating the clonal origin of both carcinomas. It is possible that cells from the foci of endometrial intraepithelial carcinoma migrate to the fallopian tube and lead to the peritoneal spread of the disease. Differential diagnosis of uterine serous carcinoma and ovarian serous carcinoma is difficult; testing ER and PR profiles and evaluation of WT1 expression can prove helpful. In recent years, it has been found that uterine serous carcinoma can be associated with the carrier state of mutated BRCA1. These studies are significant since in carriers of mutated BRCA1, apart from prophylactic adnexectomy, hysterectomy should be considered as well. Another important aspect in such cases is therapy with PARP inhibitors.
PL
Rak endometrium jest najczęstszym nowotworem złośliwym żeńskich narządów płciowych w krajach wysoko rozwiniętych. To heterogenny nowotwór o zróżnicowanych czynnikach ryzyka, stanach przedrakowych, przebiegu klinicznym i rokowaniu. Większość przypadków ma charakter sporadyczny, jednak kobiety z zespołem Lyncha mają rodzinne predyspozycje do powstania tego nowotworu, rozwijającego się u 8–12% z nich. Mutacje w MLH1, MSH2 i MSH6 występują z równą częstością. Najnowsze badania molekularne raka endometrium wskazują, że klasyczny podział według Bokhmana – na dwa typy – jest niewystarczający, zwłaszcza w obrębie rzadszego typu II, w którym stwierdzane są zarówno raki surowicze, jak i jasnokomórkowe. Za zmianę prekursorową raka surowiczego endometrium (uterine serous carcinoma) uznaje się śródnabłonkowego raka surowiczego (endometrial intraepithelial carcinoma). W badaniach immunohistochemicznych (p53, Ki67, ER i PR) wykazuje on podobieństwo do zmiany prekursorowej surowiczego raka jajnika (serous ovarian carcinoma), co może świadczyć o klonalnym pochodzeniu obu raków. Istnieje możliwość, że komórki z ognisk śródnabłonkowego raka surowiczego migrują do jajowodu i prowadzą do śródotrzewnowego rozsiewu choroby. Rozróżnienie raka surowiczego endometrium i surowiczego raka jajnika jest trudne; pomocne są badania profilu ER, PR i ocena ekspresji WT1. W ostatnich latach stwierdzono, iż rak surowiczy endometrium może mieć związek z nosicielstwem zmutowanego BRCA1. Badania te są istotne, gdyż u nosicieli zmutowanego BRCA1 oprócz profilaktycznej adneksektomii powinno się rozważyć również histerektomię. Innym ważnym aspektem byłaby w tych przypadkach terapia przy pomocy inhibitorów PARP.
Discipline
Publisher

Year
Volume
13
Issue
1
Pages
5-10
Physical description
Contributors
  • Klinika Perinatologii i Chorób Kobiecych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Krzysztof Drews
  • Klinika Onkologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Rodryg Ramlau
  • Klinika Perinatologii i Chorób Kobiecych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Krzysztof Drew
  • Klinika Onkologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Rodryg Ramlau
References
  • Ali AT: Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer 2014; 24: 384–393.
  • Colombo N, Preti E, Landoni F et al.; ESMO Guidelines Working Group: Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi33–vi38.
  • Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup: Endometrial cancer state of the science meeting. Int J Gynecol Cancer 2009; 19: 134–140.
  • Brinton LA, Felix AS, McMeekin DS et al.: Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 2013; 129: 277–284.
  • Huang M, Djordjevic B, Yates MS et al.: Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer 2013; 119: 3027–3033.
  • Lindor NM: Lynch syndrome 101 (years, that is). Am Soc Clin Oncol Educ Book 2014: 27–32.
  • Rijcken FE, Mourits MJ, Kleibeuker JH et al.: Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91: 74–80.
  • Ring KL, Connor EV, Atkins KA et al.: Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics. Int J Gynecol Cancer 2013; 23: 853–860.
  • Zhu C, Luo J, Shi H et al.: Expression of tubulin, p53, Ki67, receptors for estrogen, and progesterone in endometrial cancer. Eur J Gynecol Oncol 2009; 30: 514–517.
  • Zarbo G, Caruso G, Zammitti S et al.: The effects of tamoxifen therapy on the endometrium. Eur J Gynaecol Oncol 2000; 21: 86–88.
  • Wolfman W, Leyland N, Heywood M et al.; Society of Obstetricians and Gynaecologists of Canada: Asymptomatic endometrial thickening. J Obstet Gynaecol Can 2010; 32: 990–999.
  • Kreizman-Shefer H, Pricop J, Goldman S et al.: Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagn Pathol 2014; 9: 77.
  • Chakravarty D, Srinivasan R, Ghosh S et al.: Estrogen receptor β1 and the β2/βcx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer 2007; 17: 905–913.
  • Lehner R, Enomoto T, McGregor JA et al.: Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma. Acta Obstet Gynecol Scand 2002; 81: 162–167.
  • Lin LL, Brown JC, Segal S et al.: Quality of life, body mass index, and physical activity among uterine cancer patients. Int J Gynecol Cancer 2014; 24: 1027–1032.
  • Ballard-Barbash R, Friedenreich CM, Courneya KS et al.: Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104: 815–840.
  • Reid-Nicholson M, Iyengar P, Hummer AJ et al.: Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006; 19: 1091–1100.
  • Sherman ME: Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13: 295–308.
  • Tashiro H, Isacson C, Levine R et al.: p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150: 177–185.
  • Zheng W, Liang SX, Yi X et al.: Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol 2007; 26: 38–52.
  • Zheng W, Liang SX, Yu H et al.: Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004; 12: 207–223.
  • Roelofsen T, van Kempen LC, van der Laak JA et al.: Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion? Int J Gynecol Cancer 2012; 22: 457–464.
  • Chiaffarino F, Parazzini F, Decarli A et al.: Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol 2005; 97: 318–322.
  • Crum CP, McKeon FD, Xian W: BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 2012; 22 Suppl 1: S29–S34.
  • Soslow RA, Pirog E, Isacson C: Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 2000; 24: 726–732.
  • Sho T, Hachisuga T, Nguyen TT et al.: Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma. Int J Gynecol Cancer 2014; 24: 102–106.
  • Hedley C, Sriraksa R, Showeil R et al.: The frequency and significance of WT-1 expression in serous endometrial carcinoma. Hum Pathol 2014; 45: 1879–1884.
  • Togami S, Sasajima Y, Oi T et al.: Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci 2012; 103: 926–932.
  • Bruchim I, Amichay K, Kidron D et al.: BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer 2010; 20: 1148–1153.
  • Rafii S, Davson P, Wiliams S et al.: Is uterine serous carcinoma a part of hereditary breast cancer syndrome? J Clin Oncol 2013; 31 Suppl: abstr 5587.
  • Setiawan VW, Yang HP, Pike MC et al.: Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013; 31: 2607–2618.
Document Type
review
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-78d1eeda-4fbc-4046-9cfd-be64e49af241
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.